Document is current

Any future updates will be listed below

Correction to: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial

Crossref DOI link: https://doi.org/10.1007/s00277-021-04545-5

Published Online: 2021-05-12

Published Print: 2021-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark